Nicola Wealth Management LTD. Increases Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Nicola Wealth Management LTD. lifted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 17.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,000 shares of the company’s stock after acquiring an additional 13,000 shares during the period. Nicola Wealth Management LTD. owned 0.06% of Ionis Pharmaceuticals worth $3,485,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. nVerses Capital LLC acquired a new stake in Ionis Pharmaceuticals in the second quarter valued at $29,000. GAMMA Investing LLC lifted its holdings in Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after acquiring an additional 303 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in Ionis Pharmaceuticals in the second quarter valued at $37,000. Mather Group LLC. lifted its holdings in Ionis Pharmaceuticals by 35.8% in the second quarter. Mather Group LLC. now owns 911 shares of the company’s stock valued at $39,000 after acquiring an additional 240 shares during the period. Finally, Capital Performance Advisors LLP acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at $40,000. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on IONS shares. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Barclays lifted their price target on Ionis Pharmaceuticals from $45.00 to $51.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Bank of America boosted their target price on shares of Ionis Pharmaceuticals from $67.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Wells Fargo & Company cut their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.65.

Ionis Pharmaceuticals Stock Down 0.5 %

NASDAQ IONS traded down $0.18 on Thursday, reaching $37.60. The company had a trading volume of 193,896 shares, compared to its average volume of 1,307,251. The firm has a market capitalization of $5.94 billion, a PE ratio of -15.37 and a beta of 0.39. Ionis Pharmaceuticals, Inc. has a 1 year low of $35.95 and a 1 year high of $54.44. The firm has a 50-day moving average of $40.09 and a 200-day moving average of $42.84. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.